Moteur de recherche d’entreprises européennes
Financement de l’UE (4 684 998 €) : Inhibition de la PRopagation des protéines mal repliées dans les maladies neurodégénératives - Sofia réf. : 116060 Hor01/03/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Inhibition de la PRopagation des protéines mal repliées dans les maladies neurodégénératives - Sofia réf. : 116060
Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic directions for Alzheimer’s and Parkinson’s disease. This requires a pre-clinical stage of development that has yet to be met. The scale of neurodegenerative disease burden in Europe calls for an unprecedented research effort that can only be achieved through collaboration between leading European laboratories and the pharmaceutical industry. To meet this ambition the IMPRiND consortium will synergistically accelerate progress to map and target critical steps in the propagation, proteostatic response and protection against misfolded α-synuclein and tau. Specifically we aim to (1) identify disease-relevant assemblies, imprint their biological properties in vitro and generate homogeneous populations to assay and interfere with their pathogenic effects; (2) develop and miniaturise assays to monitor secretion, uptake, clearance and oligomerisation using bimolecular fluorescence complementation of oligomeric species or transfer of untagged assemblies to fluorescently labelled fibril-naïve cells and measure markers of early proteotoxicity that are suitable for live imaging high content screens; (3) deliver robust validation assays for these molecular events in complex cellular systems with greater functional resemblance to the native milieu of the brain such as iPSC-based and organotypic cultures (4) standardise pathological readouts in animal models for in vivo validation of modifiers, correlate them with novel peripheral or in situ markers using microdialysis to accelerate the assessment of therapeutic interventions and relevance to humans, e.g. by transplantation of human iPSC neurons in animals; (5) assess toxicity and druggability of potential targets. IMPRiND will construct this entire pipeline to examine the prion-like properties of α-synuclein and tau and test their tractability against disease progression.
| Aarhus Universitet | 208 000 € |
| ABBVIE DEUTSCHLAND GmbH & Co. KG | 0,00 € |
| Centre National de la Recherche Scientifique CNRS | 327 000 € |
| DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN e. V. | 835 625 € |
| Eli Lilly and Company Ltd. | 0,00 € |
| H. Lundbeck AS | 0,00 € |
| Idryma Iatroviologikon Ereunon Akademias Athinon | 360 000 € |
| Institut de Recherches Servier | 0,00 € |
| Institut National de la Sante et de la Recherche Medicale | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| NOVARTIS PHARMA AG | 0,00 € |
| SCIPROM Sàrl | 20 000 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 899 836 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 652 330 € |
| United Kingdom Research and Innovation | 240 207 € |
| UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS | 217 000 € |
| Universite de Bordeaux | 505 000 € |
| University of Dundee | 0,00 € |
| VIB VZW | 420 000 € |
https://cordis.europa.eu/project/id/116060
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.